It has been another successful year for Optometry and Vision Science and an eventful year in scholarly publishing. It has been my tradition to reflect and give thanks to the many who have supported the journal over the past year: authors, reviewers, and editors. This is also a good time to take stock of some of the many accomplishments in 2022.
In 2022, Optometry and Vision Science published 70 original investigations and 33 clinical case reports, and results from 5 clinical trials. The journal continues to have a strong reputation among the top-tier journals in eye and vision research as a reputable home for original research and clinical case reports for a worldwide audience. As reported in my August editorial this year, Optometry and Vision Science achieved an all-time high for several journal metrics including the 2-year Journal Impact Factor and 5-year Journal Impact Factor. Total citations to the journal were more than 9600 last year, which places us among the top 25%; there were only 2200 journals in clinical medicine qualify for consideration in this category, and we are proud to be ranked so highly among them.
The journal now ranks 16th among 124 titles in ophthalmology and 1st in optometry by h-index. The journal has also reached an all-time high for impact factor for both 3- and 5-year rankings (2.0 and 2.2, respectively). None of these accomplishments would be possible without our authors who submit their work for publication, and our peer reviewers who work to ensure that the articles published in Optometry and Vision Science are top quality. Thank you!
To our community of reviewers, this past year the editorial office engaged more than 500 different individual reviewers. Thank you to each of you for your reviewers and for your service to the journal. Thanks too for setting and upholding high standards on scientific rigor through your reviews.
To our global community of authors, thank you for submitting your work to Optometry and Vision Science. This past year, we have reduced our review and publication timelines further as we strive to provide the best possible author experience. Our goal is to be your first choice for publishing articles meant to reach optometry professionals and vision researchers. Thank you for trusting Optometry and Vision Science with your research submissions.
Future publishing is poised to change in 2023. On August 25, 2022, the Executive Office of the President's Office of Science and Technology Policy released a memo with the subject line: Ensuring Free, Immediate, and Equitable Access to Federally Funded Research. The eight-page memo mandates that by December 31, 2025, all federally funded research will be immediately available upon publication. This federal policy was first floated in February 2019 under the Trump administration before it was set aside when the COVID global pandemic took center stage. Now that this policy is again moving forward, it will further advance the agenda of the U.S. federal government to ensure unfettered access to the knowledge generated by publicly funded research. This will disrupt existing business models for academic publishing, and it is not yet entirely clear how this will impact publishers and publishing.
Next month, Optometry and Vision Science will mark its first century of continuous publication with its 100th volume. The January issue will begin the year with a feature issue on myopia. We are excited to bring this collection of articles to our readers and the community of clinicians and researchers who are actively engaged in addressing this next global pandemic: myopia.
So, what will this next 100 years bring? I am excited to find out, but without question, Optometry and Vision Science will continue to publish quality vision and biomedical eye research. Our mission will remain focused on advancing patient care through research and discovery.
I hope you have a happy holiday season and prosperous New Year!
Michael D. Twa, OD, PhD, FAAO
Editor in Chief
Optometry and Vision Science
University of Houston College of Optometry